This is a VERY important article. As you-all may or may not know (and not necessarily, seeing as how there has been almost zero coverage), Astellas Pharmaceuticals is trying to buy Ocata. Now for a recap, for those who don’t know. Ocata, of course, holds the patents for stem cell-based treatments to a long list of incurable diseases. Their FDA-approved study for a cure for age-related macular degeneration has finished Phase I. AMD affects 220 million people in the world– yep, that’s right, 220 million– and is the number one cause of blindness in the developed world. A Phase I trial is only required to show safety. Ocata’s trial showed major improvement in over half the subjects, and stopped the progression of the original disease in all but one. These gains have been maintained for several years.
Most drugs currently for sale on the market for any purpose at all do not have results like this. Yep, I’m going to say it again; most approved drugs that have completed all phases of testing and can be bought at Walmart with your doctor’s prescription do not have a success rate like this. That’s not even mentioning the cures in earlier phases of testing, the ones for multiple sclerosis, rheumatoid arthritis, Crohn’s disease, lupus, chronic fatigue, and on and on and on. And… the company’s in danger of being bought out.
Not all of the retail shareholders agree with me on this, but given the insane unending demonizing of embryonic stem cell research in this country, I will be okay with seeing this go to Japan if that’s what it takes to make these cures happen. BUT… and it’s a big but… Ocata is giving it away for almost nothing. Now THAT, we can do something about. We are standing firm against the unacceptable offers that Astellas has made so far. And we’re getting some press at last! 🙂 Read and share!!
Small investors oppose Ocata sale; $379M offer deemed too low for drug ‘worth billions’